Molecular docking and pharmacogenomics of alkaloids and their monomeric precursors; vindoline and catharanthine

Serkan Sertel, Yujie Fu, Yuangang Zu, Blanka Rebacz, Badireenath Konkimalla, Peter K. Plinkert, Alwin Krämer, Jürg Gertsch, Thomas Efferth

► To cite this version:

Serkan Sertel, Yujie Fu, Yuangang Zu, Blanka Rebacz, Badireenath Konkimalla, et al.. Molecular docking and pharmacogenomics of alkaloids and their monomeric precursors; vindoline and catharanthine. *Biochemical Pharmacology*, 2011, 81 (6), pp.723. 10.1016/j.bcp.2010.12.026 . hal-00672298

HAL Id: hal-00672298

<https://hal.science/hal-00672298>

Submitted on 21 Feb 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Accepted Manuscript

Title: Molecular docking and pharmacogenomics of *Vinca* alkaloids and their monomeric precursors; vindoline and catharanthine

Authors: Serkan Sertel, Yujie Fu, Yuangang Zu, Blanka Rebacz, Badireenath Konkimalla, Peter K. Plinkert, Alwin Krämer, Jürg Gertsch, Thomas Efferth

PII: S0006-2952(11)00013-X
DOI: doi:10.1016/j.bcp.2010.12.026
Reference: BCP 10794

To appear in: *BCP*

Received date: 17-11-2010
Revised date: 23-12-2010
Accepted date: 24-12-2010

Please cite this article as: Sertel S, Fu Y, Zu Y, Rebacz B, Konkimalla B, Plinkert PK, Krämer A, Gertsch J, Efferth T, Molecular docking and pharmacogenomics of *Vinca* alkaloids and their monomeric precursors; vindoline and catharanthine, *Biochemical Pharmacology* (2010), doi:10.1016/j.bcp.2010.12.026

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Molecular docking and pharmacogenomics of *Vinca* alkaloids and their monomeric precursors, vindoline and catharanthine

Serkan Sertel ^{a, e, g}, Yujie Fu ^{b, c}, Yuangang Zu ^{b, c}, Blanka Rebacz ^d, Badireenath Konkimalla^e, Peter K. Plinkert ^a, Alwin Krämer ^d, Jürg Gertsch ^e and Thomas Efferth ^{e, f, g, *}

^a *Department of Otorhinolaryngology, Head and Neck Surgery, University of Heidelberg, Heidelberg, Germany*

^b *Key Laboratory of Forest Plant Ecology, Ministry of Education, Northeast Forestry University, Harbin, China*

^c *Engineering Research Center of Forest Bio-Preparation, Ministry of Education, Northeast Forestry University, Harbin, China*

^d *Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center and Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany*

^e *Pharmaceutical Biology (C015), German Cancer Research Center, Heidelberg, Germany*

^f *Institute of Biochemistry and Molecular Medicine, University of Bern, Bern, Switzerland*

^g *Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, University of Mainz, Mainz, Germany*

*** Corresponding Author:** Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, University of Mainz, Staudinger Weg 5, 55128 Mainz, Germany.

Phone: +49-6131-3925751; Fax: +49-6131-3923752; E-mail: efferth@uni-mainz.de

Running Title: Pharmacogenomics of *Vinca* Alkaloids

Keywords: centrosomal clustering, molecular docking, multidrug resistance, pharmacogenomics, vinca alkaloids

Abbreviations: ABC transporter, ATP-binding cassette transporter; HNSCC, head and neck squamous cell carcinoma; IC₅₀, 50% inhibition concentration; RMSD, root mean square deviations; mRNA, messenger RNA; NCI, national cancer institute

Abstract

Vinblastine and vincristine are dimeric indole alkaloids derived from *Catharanthus roseus* (formerly: *Vinca rosea*). Their monomeric precursor molecules are vindoline and catharanthine. While vinblastine and vincristine are well-known mitotic spindle poisons, not much is known about vindoline and catharanthine. Vindoline and catharanthine showed weak cytotoxicity, while vinblastine, vincristine, and the semisynthetic vindesine and vinorelbine revealed high cytotoxicity towards cancer cells. This may reflect a general biological principle of poisonous plants. Highly toxic compounds are not only active towards predators, but also towards plant tissues. Hence, plants need mechanisms to protect themselves from their own poisons. One evolutionary strategy to solve this problem is to generate less toxic precursors, which are dimerized to toxic end products when needed. As shown by *in silico* molecular docking and biochemical approaches, vinblastine, vincristine and vinorelbine bound with high affinity to α/β -tubulin and inhibited tubulin polymerization, whereas the effects of vindoline and catharanthine were weak. Similarly, vinblastine produced high fractions of mono- and multipolar mitotic spindles, while vindoline and catharanthine did only weakly affect bipolar mitotic spindle formation. Inhibition of centrosomal clustering represents a treatment novel strategy leading to multipolar spindle formation and apoptosis. This has been shown for vinblastine by us for the first time. P-glycoprotein-overexpressing multidrug-resistant CEM/VCR1000 cells were highly resistant towards vincristine and cross-resistant to vinblastine, vindesine, and vinorelbine, but not or only weakly cross-resistant to vindoline and catharanthine. In addition to tubulin as primary target, microarray-based mRNA signatures of responsiveness of these compounds have been identified by COMPARE and signaling pathway profiling.

1. Introduction

Plants produce secondary metabolites as defense weapons against microbial infections by viruses, bacteria, or protozoa and parasites such as insects or worms as well as against herbivores. Many plants are poisonous, while others can serve as medicinal plants with pharmacological activity. As shown in a previous survey conducted by the National Cancer Institute (NCI), USA, more than two thirds of all anticancer drugs established in anticancer therapy are natural products, derivatives of natural products or mimic bioactive principles of natural products [1].

Among the clinically established natural products with anticancer activity are the *Vinca* alkaloids vinblastine and vincristine and more recently, the semi-synthetic derivatives vindesine and vinorelbine, which are highly useful drugs for the treatment of certain malignancies.

Vinca alkaloids arrest tumor cells during mitosis by binding to tubulin and depolymerization of microtubules [2]. This leads to cell cycle arrest in mitosis [3]. Besides interaction of *Vinca* alkaloids with tubulins, other mechanisms upstream (*e.g.* membrane-bound drug efflux transporters) and downstream (*e.g.* signal transduction pathways, programmed cell death) also account to the drugs' efficacy towards cancer cells.

Vinblastine and vincristine are dimeric indole alkaloids derived from *Catharanthus roseus* (formerly: *Vinca rosea*). Their monomeric precursor molecules are vindoline and catharanthine. While there is clear evidence for the action of vinblastine and vincristine as mitotic spindle poisons, not much is known about the monomers vindoline and catharanthine.

Both precursor molecules are less cytotoxic than their dimeric drugs, vinblastine and vincristine. The question arises, whether this reflects a biological principle of poisonous plants. Poisonous natural products such as vinblastine and vincristine are effective defence mechanisms against herbivores and other predators. However, these compounds may also reveal toxicity to the plants themselves. Hence, they may generate and store large amounts of less toxic precursor molecules for self-protection, whereas the final synthesis of highly toxic end products occurs only upon appropriate external stimulation.

In the present investigation, we hypothesized that different cytotoxicities of monomeric precursors and dimeric end products should affect binding to the primary target of *Vinca* alkaloids, the microtubules. In addition, dimeric second-generation drugs, the semisynthetic vindesine and vinorelbine have been included in the study. A comparative analysis of functional effects of the above mentioned compounds on microtubule formation

(effect on α/β -tubulin polymerisation) has been carried out *in vitro*. The relative binding affinities of vindoline and catharanthine were estimated from Dixon plots assuming that all compounds either directly or indirectly (allosteric modulation) interfere with the [^3H]-vinblastine binding sites in α/β -tubulin. The experimental data have been compared to molecular modelling studies. The binding of *Vinca* alkaloids to tubulin may not only cause inhibition of microtubule elongation, but may also affect mitotic spindle formation. The formation of multipolar mitotic spindles by inhibition of centrosomal coalescence has been anticipated as novel treatment strategy [4,5]. Therefore, we have analyzed the capacity of *Vinca* alkaloids to induce multipolar mitotic spindles. Finally, we have analyzed the role of drug resistance mechanisms for monomeric and dimeric *Vinca* alkaloids. We first analyzed cross-resistance of vincristine-resistant CEM/VCR1000 leukemia cells towards vindoline and catharanthine in comparison to vinblastine, vindesine, and vinorelbine. Then, we have analyzed other determinants of responsiveness towards *Vinca* alkaloids in the cell line panel of the NCI by means of COMPARE-analyses of microarray-based transcriptome-wide mRNA expression.

2. Material and Methods

2.1. Compounds

Vindoline and catharanthine were isolated from *Cataranthus roseus* as described [6]. Vinblastine sulphate, vincristine sulphate, vindesine sulphate salt, and vinorelbine ditartrate salt vindesine were obtained from Sigma-Aldrich (Taufkirchen, Germany). Vindoline and catharanthine are precursor molecules in the biosynthesis route, while vinblastine and vincristine are end products (**Figure 1**). The entire biosynthesis pathway has previously been elucidated [7]. Vindoline and catharanthine were isolated from *Cataranthus roseus* by two of the authors (YF and YZ). Vindesine and vinorelbine are semi-synthetic derivatives and were obtained from Sigma-Aldrich (Taufkirchen, Germany).

2.2. Cell lines

Human CCRF-CEM leukemia cells were maintained in RPMI medium (Gibco, Eggenstein, Germany) supplemented with 10% fetal calf serum in a humidified 7% CO₂ atmosphere at 37°C. Cells were passaged twice weekly. All experiments were performed with cells in the logarithmic growth phase. The multidrug resistance gene 1 (*ABCB1*, *MDR1*)-expressing CEM/VCR1000 subline was maintained in 1000ng/mL vincristine. The establishment of the resistant subline has been described [8]. Sensitive and resistant cells were kindly provided by Dr. A. Sauerbrey (Dept. of Pediatrics, University of Jena, Jena, Germany).

The HNSCC cell line SCC114 (oral squamous cell carcinoma) cells were cultured in Dulbecco's modified Eagle's Medium (DMEM, Gibco, Invitrogen, Karlsruhe, Germany) supplemented with 10 % FCS (Biochrom AG, Berlin, Germany). When indicated, vindoline, catharanthine, or vinblastine were added to the cell culture medium for 24 h. In all experiments, the final DMSO concentration was <1%.

The panel of 60 human tumor cell lines of the Developmental Therapeutics Program of the NCI consisted of leukemia, melanoma, non-small cell lung cancer, colon cancer, renal cancer, and ovarian cancer cells, cells of tumors of the central nervous system, prostate carcinoma, and breast cancer. Their origin and processing have been previously described [9].

2.3. Sulforhodamine B assay

The determination of drug sensitivity in the NCI cell lines by the sulforhodamine B assay has been reported [10]. The 50% inhibition concentration (IC₅₀) values for vinblastine, vincristine, catharanthine, and vindoline have been deposited in the database of the database of the Developmental Therapeutics Program of the NCI (<http://dtp.nci.nih.gov>).

2.4. Growth inhibition assay

The *in vitro* response to drugs was evaluated by means of a growth inhibition assay as described [10]. Aliquots of 5×10^4 cells/ml were seeded in 24-well plates and compounds were immediately added at different drug concentrations to allow calculation of 50% inhibition concentration (IC₅₀) values. Cells were counted seven days after drug treatment. The resulting growth data represent the net outcome of cell proliferation and cell death.

2.5. Preparation of pure α/β -tubulin (>95%)

Tubulin was isolated as pure α/β -tubulin from fresh pig brain according to a previously described method [11]. Fresh brains were obtained from the local slaughterhouse and processed immediately without prior cooling. In brief, 150-200 g cleaned pig brain was put into ice-cooled depolymerization buffer (50 mM MES, 1 mM CaCl₂, adjusted to pH 6.9 with KOH) and homogenized in a Polytron mixer. The homogenate was centrifuged in a Sorvall SLA-1500 rotor at 14,500 rpm for 60 min. The supernatant was transferred into an Erlenmeyer flask in high-molar PIPES-buffer (1 M PIPES, 10 mM MgCl₂, 20 mM EGTA adjusted to pH 6.9 with KOH) plus ATP (1.5 mM final concentration) and glycerol (98%) ad 300 mL. The resulting suspension was mixed and incubated at 37°C for 1 h. Aliquots were transferred into ultracentrifuge tubes and centrifuged in a Beckman Ti50.2 rotor at 32,500 rpm (96,000×g) for 75 min at 30°C. The microtubule protein pellets were suspended in depolymerization buffer and put on ice prior to ultracentrifugation at 4°C. The procedure was repeated for two polymerization cycles (total of three cycles) and the final α/β -tubulin pellets were suspended in ice-cold Brinkley Buffer (BRB80; 80 mM PIPES, 1 mM MgCl₂, 1 mM

EGTA adjusted to pH 6.8 with KOH) prior to shock-freezing in liquid nitrogen and subsequent storage at -80°C. Purity and concentration of α/β -tubulin were determined by SDS-PAGE gel electrophoresis and spectrophotometrically ($A = \epsilon \cdot c \cdot d$ with a given extinction coefficient of $115,000 \text{ M}^{-1} \text{ cm}^{-1}$) at 280 nm. This procedure typically yielded 60-100 mg of α/β -tubulin per 100 g of brain.

2.6. Radioligand displacement α/β -tubulin

Tubulin in BRB80 buffer (0.5 mL, 5-10 μM) was incubated with two different concentrations of [$\text{G-}^3\text{H}$]-vinblastine (American Radiolabeled Chemicals, Inc.) (5 and 10 μM) on ice for 30 min. Different concentrations of unlabeled vindoline, catharanthine, vincristine, vindesine, or vinorelbine were added and the mixture was incubated at 37°C for 30 min. DMSO was used as vehicle control. Bound radioactivity was separated by gel filtration on a Sephadex G50 column on micro columns and measured in a scintillation counter.

2.7. Turbidimetry analysis of polymer formation

Freshly thawed α/β -tubulin was centrifuged at $5,000\times g$ for 5 min at 5°C and then incubated with additional BRB80 buffer, drugs, DMSO vehicle, GTP/glutamate (25 mM/2.7 M) and/or MAPs, respectively, in a 96-well plate in either 50 or 100 μL volumes. Experiments were either carried out in a 96-well quartz plate or in normal 96-well polystyrene plates (Falcon). The polymerization was monitored real-time at 340 nm in a temperature-controlled TECAN GeniosPro spectrophotometer. Depending on the specific experiment, the temperature was set either to RT (actual measuring temperature was 24-27°C) or 37°C. The concentration of DMSO was found to be highly critical, because concentrations $>2\%$ DMSO induced considerable MT formation. UV absorption of compounds was subtracted from absorption curves. All experiments, along with both negative (untreated α/β -tubulin) and vehicle controls, were carried out in triplicate. Experiments were performed at least with two different α/β -tubulin batches.

2.8. Immunofluorescence

Cells grown on cover slips were fixed in -20°C methanol/acetone (1:1) for 7 min and then blocked in 10% goat serum/PBS. The primary mouse monoclonal antibody to Eg5 (Transduction Laboratories, Lexington, KY) was incubated for 1 h following 30 min incubation with a fluorochrome-conjugated secondary antibody anti-mouse Cy3 (Jackson ImmunoResearch Laboratories, West Grove, PN). Immunostained cells were examined using a Zeiss Axiovert 200 M fluorescence microscope (Göttingen, Germany) and images were processed with Photoshop software (Adobe, Munich, Germany).

Kinesin-related motor protein Eg5 (also known as kinesin-like protein KIF11, kinesin-like spindle protein HKSP) is localized at the centrosomes, spindle microtubules, and intracellular bridge. Eg5 is required for establishing the bipolar spindle.

2.9. Molecular docking of *Vinca* alkaloids on tubulin

The x-ray structure of tubulin–colchicines–vinblastine: stahmnin-like domain complex (SLD) was used as docking template throughout the docking calculations. The coordinates of vinblastine were extracted from the PDB file, obtained from the Brookhaven Protein Data Bank (PDB 1Z2B) [12]. Docking calculations were performed using AutoDock program (AutoDock 4.2, The Scripps Research Institute, La Jolla, CA, USA) installed on a Linux PC under the SuSe operating system. AutoDock is an automated and robust docking algorithm based on the Lamarckian genetic algorithm (GA) with several success rates in the virtual screening of ligands.

The 2D structures of vincristine, vinblastine, vinorelbine, videsine, cantharanthine and vindoline were energy-minimised and converted to 3D structures compatible for docking operation using an open source program PRODRG [13].

Prior to start of the docking operation, essential hydrogens and Gasteiger chargers were added to the macromolecule. In order to sample the binding site, a grid of 60 Å×60 Å×60 Å with a spacing of 0.375 Å was first computed. In total, 100 cycles of flexible ligand docking were performed in the grid representation of the receptor binding site, followed by scoring the ligand-receptor interaction. AutoDock clustering was performed based on similarities in binding modes and affinities in these cycles. The optimized orientations represent possible binding modes of the ligand within the site. The AutoDock docking output

contains solutions ranked according to the scoring functions with information about the frequency of occurrence, mean energies, inhibition constant and low root mean square deviations (RMSD) within the cluster each defined by the 3D coordinates. PyMOL (Schrödinger, Portland, OR, USA) was used as visualization tool to further get a deeper insight on the binding modes obtained from docking [14].

2.10. Statistical analyses

The mRNA expression values of 60 cell lines of the genes of interest were selected from the NCI database (<http://dtp.nci.nih.gov>). The mRNA expression has been determined by microarray analyses [15,16]. COMPARE analyses were performed to produce rank-ordered lists of genes expressed in the NCI cell line panel. The methodology has been described previously in detail [17]. Briefly, every gene of the NCI microarray database is ranked for similarity of its mRNA expression to the IC₅₀ values for *Vinca* alkaloids. To derive COMPARE rankings, a scale index of correlations coefficients (R-values) is created. In the standard COMPARE approach, greater mRNA expression in cell lines correlates with enhanced drug resistance, whereas in reverse COMPARE analyses, greater mRNA expression in cell lines indicates drug sensitivity.

The Ingenuity Pathway Analysis software (IPA) (Ingenuity Systems, Mountain View, CA, USA; <http://www.ingenuity.com>) was utilized to identify networks and pathways of interacting genes and other functional groups in genomic data. Using the IPA Functional Analysis tool, we were able to associate biological functions and diseases to the experimental results. Moreover, we used a biomarker filter tool and the Network Explorer for visualizing molecular relationships.

For hierarchical cluster analysis, objects were classified by calculation of distances according to the closeness of between-individual distances. All objects were assembled into a cluster tree (dendrogram). The merging of objects with similar features leads to the formation of a cluster, where the length of the branch indicates the degree of relation. The distance of a subordinate cluster to a superior cluster represents a criterion for the closeness of clusters as well as for the affiliation of single objects to clusters. Thus, objects with tightly related features appear together, while separation in the cluster tree increases with progressive dissimilarity. Recently, cluster models have been validated for gene expression profiling and for approaching molecular pharmacology of cancer [15,18]. Cluster analyses applying the WARD method were done with the WinSTAT program (Kalmia, Cambridge, MA, USA)).

1 Missing values were automatically omitted by the program, and the closeness of two joined
2 objects was calculated by the number of data points they contained. In order to calculate
3 distances between all variables included in the analysis, the program automatically
4 standardizes the variables by transforming the data with a mean = 0 and a variance = 1.
5
6

7 Pearson's correlation test was used to calculate significance values and rank
8 correlation coefficients as a relative measure for the linear dependency of two variables. This
9 test was implemented into the WinSTAT Program.. Pearson's correlation test determines the
10 correlation of rank position of values. Ordinal or metric scaling of data is suited for the test
11 and data are transformed into rank positions. There is no condition regarding normal
12 distribution of the data set for the performance of Pearson's correlation test.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

3. Results

3.1. Cytotoxicity

The NCI cell line panel has been tested for sensitivity towards vinblastine, vincristine, catharanthine, or vindoline. The mean $\log_{10}IC_{50}$ values of eight different tumor types for these compounds are shown in **Figure 2**. Cell lines of all tumor types revealed high cytotoxicity with mean $\log_{10}IC_{50}$ values for vinblastine in a range of -9.26 ± 0.04 M (leukemia) to -8.15 ± 0.41 M (ovarian carcinoma) and for vincristine in a range of -6.95 ± 0.01 M (leukemia) to -6.14 ± 0.49 M (breast cancer). Catharanthine and vindoline displayed only weak activity.

3.2. Inhibition of tubulin polymerization by *Vinca* alkaloids

Vincristine potently inhibited microtubule assembly and catharanthine showed a less potent effect on α/β -tubulin polymerization (**Figure 3**). Vindoline was not able to reach considerable inhibition of microtubule assembly, suggesting that this compound does not or only very weakly interact with α/β -tubulin. In addition, we analyzed the semi-synthetic derivatives, vindesine and vinorelbine. Both drugs inhibited microtubule assembly in a comparable manner as vincristine (**Figure 3**).

3.3. Uncompetitive inhibition of the binding [3H]vinblastine to tubulin by catharanthine

In competition experiments, catharanthine clearly interfered with [3H]-vinblastine for α/β -tubulin binding in an apparently uncompetitive manner (**Figure 4**). Uncompetitive inhibition takes place, when a tubulin ligand (here catharanthine) binds only to the complex formed between tubulin and vinblastine (the T-V complex).

3.4. Molecular docking

The x-ray structure of vinblastine bound to tubulin in a complex with the RB3 protein stathmin-like domain was selected as a docking template (PDB 1Z2B) [19]. The template and

the docking parameters, using AutoDock, were validated by docking the crystallographic structure of vinblastine into the binding site of the protein template. Docking results showed low RMSD values between the experimental and the calculated docked structure and set a good platform to reliably dock other structurally similar chemical molecules. *Vinca* alkaloids were individually docked into the validated grid defined in the crystal structure of α/β -tubulin for appropriate conformational search. Next, 100 cycles of docking with approximately 250,000 energy evaluations in each cycle were carried out without any flexibility constraints on the ligand. The results were finally analyzed upon setting identical conditions for docking the tubulin structure template with vincristine, vinblastine, vinorelbine, vindesine, catharanthine and vindoline chemical molecules throughout the operation (**Figure 5**).

The final docking results show that vindesine, vincristine, vinorelbine and vinblastine possess a high-order in the frequency of occurrence in a cluster and closeness in parameters in terms of mean docking energy (-8.52, -8.50, -8.47 and -8.37 kcal/mol respectively) and predicted inhibition constant (1.49, 2.05, 1.54, 1.67 μ M) as shown in **Table I**. In contrast, vindoline and catharanthine showed relatively low mean docking energies (-7.28 and -7.0 kcal/mol, respectively) and inhibition constants (4.72 and 7.34 μ M, respectively) (**Table I**), which implies a low affinity to tubulin binding.

The ligand-protein interaction was analyzed using the LPC tool [20]. Binding site analysis showed that interaction of *Vinca* alkaloids (except of catharanthine) with Asn249C was a conserved feature (**Table II**). Interaction of Val177B was observed for four of the six *Vinca* alkaloids analyzed and interaction of Pro175B with three compounds (**Table II**). No H-bond interaction of catharanthine to any amino acid in the pharmacophore was found. The four clinically established *Vinca* alkaloids revealed 12-15 residues involved in hydrophobic interaction with the ligand, whereas vindoline and catharanthine exerted hydrophobic interaction with only 9 residues each.

3.5. Induction of mono- and multipolar mitoses

To analyze whether vinblastine and its precursors, vindoline and catharanthine, exert a part of their poisonous effects by induction of multipolar mitotic spindles, SCC114 cells were treated for 24 h with each of the three compounds and immunostained with an anti-Eg5 monoclonal antibody to visualize mitotic figures. Counterstaining of DNA was done using DAPI. As shown in **Figure 6A**, untreated SCC114 cells contained 6.6% monopolar, 85% bipolar, and 8.3% multipolar mitoses. Treatment with 100-300 nM vindoline led to a dose-dependent increase of monopolar mitoses up to 23.5%. At higher concentrations, the fraction of monopolar mitoses decreased. At doses of 250-500 nM vindoline, a weak increase of multipolar mitoses was recorded (12-15%). Above 500 nM vindoline, general cytotoxicity precluded further analysis of mitotic spindles in SCC114 cells. According to the increase of mono- or multipolar mitoses, the fraction of bipolar mitoses dose-dependently decreased in a range between 100 and 500 nM.

Catharanthine showed a different effect on spindle polarity than vindoline. As shown in **Figure 6B**, there was a strong increase of monopolar mitoses up to 37.5% and no increase of multipolar mitoses upon treatment with 150-210 nM catharanthine. Accordingly, the percentages of bipolar mitoses dose-dependently decreased from 84% (control) to 50% (210 nM). At higher concentrations, catharanthine was cytotoxic. Vinblastine induced a considerable percentage particularly of multipolar mitoses (**Figure 6C**). Representative examples of multipolar mitoses in SCC114 cells treated with vindoline, catharanthine, or vinblastine and bipolar mitoses in untreated control cells are depicted in **Figure 7**.

3.6. Multidrug resistance

Since the activity of *Vinca* alkaloids may not only be determined by binding to tubulin as primary target, but also by mechanisms upstream of this target, we investigated the role of the multidrug resistance-conferring drug transporter, P-glycoprotein. We treated drug-sensitive, parental CCRF-CEM leukemia cells and vincristine-resistant CEM/VCR1000 cells with catharanthine, vindoline, and four clinically established *Vinca* alkaloids. Calculation of the degrees of resistance from the IC₅₀ values revealed that vincristine was one order and vinblastine two orders of magnitude more cytotoxic towards CCRF-CEM cells than catharanthine or vindoline (**Table III**), while vindesine was about two-fold less active than

vincristine, vinorelbine was two orders of magnitude more active than vincristine. CEM/VCR1000 cells were 41.8-fold resistant towards vincristine as compared to the parental CCRF-CEM cell line. Interestingly, CEM/VCR1000 cells showed higher degrees of resistance (56.2- to 341.9-fold, respectively) towards vinblastine, vindesine, or vinorelbine than the resistance-selecting agent, vincristine itself. Degrees of resistance towards catharanthine or vindoline were only low (~2-fold) (**Table III**).

3.7. Cross-resistance

To further analyze determinants of resistance and sensitivity towards *Vinca* alkaloids, we took advantage of the database of the Developmental Therapeutics Program of NCI, USA. We first analyzed the cross-resistance profile of the NCI tumor cell panel to *Vinca* alkaloids. There was a highly significant correlation between the $\log_{10}IC_{50}$ values for vinblastine and vincristine ($R=0.789$; $P=6.5 \times 10^{-16}$), whereas vincristine cytotoxicity did not correlate with catharanthine or vindoline activity (**Table IV**). The $\log_{10}IC_{50}$ values for catharanthine were significantly associated with those for vindoline ($P=0.01$), but at a low R-value (0.310). Other relationships were not found.

3.8. COMPARE analyses of microarray data

Next, we performed COMPARE analyses of the IC_{50} values for vinblastine, vincristine, vindoline, and catharanthine and the transcriptome-wide mRNA expression of the NCI cell lines to produce scale indices of correlation coefficients. We first performed a standard COMPARE analysis in which cell lines that were most inhibited by *Vinca* alkaloids (lowest IC_{50} values) were correlated with the highest mRNA expression levels of genes. Genes with correlation coefficients of $R>0.5$ are shown in **Table V**. If more than 10 genes met this criterion, only the top 10 genes for each compound are listed. If more than one clone of the same gene appeared in the COMPARE ranking lists, only the clone with the best R-value was displayed. These genes may be considered as possible candidate genes, which determine cellular resistance to *Vinca* alkaloids. Afterwards, reverse COMPARE analyses were done ($R<-0.5$), which correlated the most inhibited cell lines with the lowest gene expression levels (**Table V**). This approach provided genes that are associated with cellular sensitivity to *Vinca* alkaloids. A comparison showed that no genes appeared in association with more than one of

the compounds, indicating that different genes may determine cellular response to these compounds.

3.9. Hierarchical cluster analyses

The genes obtained by standard and reverse COMPARE analyses for vindoline, catharanthine, vinblastine and vincristine were subjected to hierarchical cluster analysis to obtain a dendrogram, where the cell lines are arranged according to their expression profile of these genes. The dendrogram for each of the *Vinca* alkaloids investigated can be divided into three major cluster branches (**Figure 8**). Then, the median $\log_{10}IC_{50}$ values for *Vinca* alkaloids were used as cut-off threshold to define cell lines as being sensitive or resistant. As can be seen in **Table VI**, the distribution of sensitive or resistant cell lines was significantly different between the branches of the dendrograms for catharanthine or vindoline, indicating that cellular response to these two *Vinca* alkaloids was predictable by these genes. Statistical significant results were not obtained for vinblastine or vincristine, indicating that the genes identified by microarray and COMPARE analyses did not predict cellular response to these two drugs.

3.10. Ingenuity Pathway Analyses

As a next step, we employed signaling route analyses. The genes identified by microarray and COMPARE analyses were subjected to Ingenuity Pathway Analysis software (version 6.5). Several groups of biological functions for genes were found to be significant in that they contained more of the identified genes than expected by chance. The genes determining sensitivity or resistance to catharanthine belonged to groups with the following biological functions: cell-to-cell signaling and interaction, developmental disorder, genetic disorder, and hematological system and development and function and other groups (**Figure 9A**). The most important groups of genes determining cellular response to vindoline were drug metabolism, molecular transport, small molecule biochemistry and genetic disorder (**Figure 9B**). Since the genes identified by COMPARE analyses did not significantly predict sensitivity and resistance to vinblastine or vincristine (**Table VI**), signaling pathway analyses were not applied for these two drugs.

Discussion

In the present investigation, we analyzed the cytotoxic potential of vindoline and catharanthine, two precursors of the mitotic spindle poisons, vinblastine and vincristine. In addition to these natural products, the semi-synthetic derivatives, vindesine and vinorelbine of the second-generation have been investigated.

A striking feature was that the monomeric precursors, vindoline and catharanthine, were less cytotoxic towards cancer cells than the dimeric drugs, vinblastine and vincristine. This may reflect a general biological principle of poisonous plants. Highly toxic compounds are not only active towards predators, but also towards plant tissues. Hence, plants need mechanisms to protect themselves from their own poisons. One evolutionary strategy to solve this problem is to generate less toxic precursors, which are dimerized to toxic end products when needed. Storage of large amounts of the less toxic precursors, vindoline and catharanthine, is possible without harm for plants. Upon appropriate stimulation, high amounts of the toxic compounds vinblastine and vincristine can rapidly be synthesized by the plants. This hypothesis is supported by the fact that radical oxygen species foster the biosynthesis of vinblastine and vincristine from its precursors, vindoline and catharanthine [7]. Exposure of periwinkle plants with H_2O_2 induced dimerization of the precursors to vinblastine [21]. Translating this experimental data to real life situations could mean that leaves attacked by plant-eating herbivores may be exposed to higher amounts of oxygen and radical oxygen species, which act as stimulus to defend the plant against the herbivore by vinblastine and vincristine production.

Microtubules are crucial for chromosomal segregation during mitosis. Clinically established *Vinca* alkaloids act as mitotic spindle poisons by inhibition of tubulin polymerization. Many cancer cells contain supernumerary centrosomes, which may contribute to aneuploidy induction *via* multipolar mitotic spindle formation. However, since spindle multipolarity is antagonistic to cell viability, tumor cells have developed centrosomal clustering mechanisms to prevent multipolar spindle formation by coalescence of multiple centrosomes into two functional spindle poles [5, 22]. Inhibition of centrosome clustering represents a novel strategy for cancer drug development and leads to the formation of multipolar spindles with subsequent apoptosis induction. SCC114 is an oral squamous carcinoma cell line characteristic for the phenotype of centrosomal clustering [4]. Even though the majority of the cell population harbours supernumerary centrosomes, only a few mitotic cells form multipolar spindles. The residual cell population coalesces their

centrosomes into two spindle poles, thus, being able to divide in a bipolar manner. In the present investigation, treatment with vinblastine induced the formation of multipolar spindles in SCC114 cells in a considerable fraction of mitoses. In contrast, treatment with much higher concentrations of both, catharanthine or vindoline, only led to very few cells showing spindle multipolarity. This indicates vinblastine may in part trigger cell death, similar to other drugs that interfere with tubulin polymerization like griseofulvin, by induction of spindle multipolarity [4]. Importantly, the capacity for multipolar spindle induction of the drugs analyzed clearly correlated with the cytotoxicity of the compounds, *i.e.* the highly cytotoxic vinblastine better induced multipolar spindle formation than the weakly cytotoxic vindoline or catharanthine. Another interesting finding was that, in contrast to vinblastine, vindoline and catharanthine preferentially induced monopolar spindles, which may be related to different functions of both monomers in the vinblastine dimer.

It has previously been reported that the vindoline moiety is necessary for anchoring, while the catharanthine moiety confers cytotoxicity [23]. This view is conceivable with our molecular docking data showing that the weakly cytotoxic vindoline shares the residue Asn249C as binding partner for vinblastine, vincristine, vindesine, and vinorelbine, whereas the intermediate cytotoxic catharanthine did not bind to any amino acid at all. This may also contribute to differential effects on the formation of mono- and multipolar mitotic spindles.

Remarkably, the less cytotoxic precursors were also less cross-resistant in multidrug-resistant CEM/VCR1000 cells (2-fold *versus* 40-to 340-fold). Because they are less toxic, there is no need for cancer cells to extrude them out of the cell by P-glycoprotein. It is unknown why the resistance of the selecting agent, vinblastine in CEM/VCR1000 is less than the cross-resistance towards non-selecting *Vinca* alkaloids (vincristine, vindesine, vinorelbine). ATP-binding cassette (ABC) transporters are not only relevant for multidrug resistance of tumor cells, but are also widely distributed in microbiology as detoxification mechanisms for xenobiotics. From an evolutionary point of view, there is less need to extrude less toxic compounds out of cells than toxic ones. ABC transporters are part of the Phase I-III system of enzymes and transporters in mammals to cope with xenobiotic compounds taken up with nutrition.

Interestingly, a high degree of cross-resistance was observed between vinblastine and vincristine, but between the precursors, vindolidine and catharanthine, and vinblastine or vincristine. This may indicate similar modes of action of vinblastine and vincristine, but not of vindoline and catharanthine. This assumption drawn from correlation analyses was substantiated by measurement of microtubule formation. The weakly active vindoline did not

inhibit tubulin polymerization and the moderately cytotoxic catharanthine inhibited tubulin polymerization only at higher concentrations as compared to the highly cytotoxic drugs vinblastine, vincristine, and vinorelbine. This result underlines the importance of tubulin as primary target of *Vinca* alkaloids in cancer therapy. Vinblastine, vincristine, vindesine and vinorelbine revealed a considerably higher binding affinity to the *Vinca* pharmacophore on tubulin as their precursors, vindoline or catharanthine. A closer inspection of amino acids in the binding region showed that all compounds except catharanthine attached to the residue Asn249C. In addition to Asn249C, each compound, except catharanthine showed H-bond interactions to variable other amino acids. Whereas vinblastine, vincristine, and vinblastine bound to 5-7 amino acids in our *in silico* docking approach, vindoline bound to only four residues and catharanthine did not show considerable interaction with amino acids in the pharmacophore. Similarly, the number of hydrophobic interactions of the clinically established *Vinca* alkaloids was higher than that of vindoline or catharanthine. This speaks for weaker interactions of vindoline and catharanthine with tubulin than of the other drugs, which nicely compares to the results on inhibition of tubulin polymerization in our biochemical assay.

In addition to binding to tubulin as primary target and P-glycoprotein as upstream mechanism of drug resistance, other molecular determinants for cellular response towards *Vinca* alkaloids may also be taken into account. Therefore, we performed COMPARE analyses of microarray-based transcriptome-wide mRNA expression profiling. It was of interest that the mRNA expression different genes (or still not assigned coding regions) correlated with sensitivity or resistance to catharanthine or vindoline, but not to vinblastine or vincristine. This may indicate that tubulin as common target may be of utmost importance for the highly cytotoxic vinblastine and vincristine. The weakly cytotoxic catharanthine and vindoline, which also only weakly bind to tubulin may have other determinants of response of tumor cells. Therefore, the hierarchical clustering were statistically significant for catharanthine or vindoline, but not for vinblastine or vincristine.

The only gene which appeared in reverse COMPARE analyses of both vinblastine and vincristine was claudin 1 (*CLDN1*). Claudins are proteins constituting tight junctions at the blood brain barrier. It has been reported that components of tight junctions confer resistance to vinblastine [24]. Hence, the role of claudin 1 for cellular response towards *Vinca* alkaloids merits further investigation in the future.

In conclusion, we found that the monomers, vindoline and catharanthine, showed weak cytotoxicity, respectively, while dimeric vinblastine, vincristine, vindesine, and

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

vinorelbine revealed high cytotoxicity towards cancer cells. As shown by *in silico* molecular docking approaches and biochemical experiments *in vitro*, vinblastine, vincristine and vinorelbine bound with high affinity to α/β -tubulin and inhibited tubulin polymerization, whereas the effects of vindoline and catharanthine were weak. Similarly, vinblastine produced high rates of multipolar mitotic spindles, while vindoline and catharanthine did only weakly affect bipolar mitotic spindle formation. P-glycoprotein-overexpressing multidrug-resistant CEM/VCR1000 cells were highly resistant towards vincristine and cross-resistant to vinblastine, vindesine, and vinorelbine, but not or only weakly cross-resistant to vindoline and catharanthine. In addition to tubulin as primary target, microarray-based mRNA signatures of responsiveness of these compounds have been identified by COMPARE and signaling pathway profiling.

Conflict of interest

There is no conflict of interest.

Legends

Figure 1: Chemical structures of *Vinca* alkaloids.

Figure 2: Log₁₀IC₅₀ values for *Vinca* alkaloids. Mean values $\pm$ SEM of 60 cell lines were grouped according to their tumor origin.

Figure 3: Inhibition of tubulin polymerization by *Vinca* alkaloids. Purified α/β -tubulin (25 μ M) was polymerized at 37°C in BRB80 assembly buffer with GTP/glutamate (25mM/2.7M) and with increasing concentrations of test compounds (μ M). Turbidity was measured at 340nm after 45min. Endpoints (Δ_{340}) mean values are plotted as a non-linear function of drug concentration $\pm$ SEM (N=3).

Figure 4: Dixon plot, uncompetitive inhibition of the binding [³H]vinblastine to tubulin by catharanthine. [³H]vinblastine at 5 μ M (black circles) and 10 μ M (white circles) was incubated with purified α/β -tubulin (10 μ M) and catharanthine (0.5–5 μ M). After centrifugal gel filtration on a Sephadex G50 column the bound [³H]-vinblastine was measured by scintillation counting. Data points are mean values of three experiments. Dotted line shows putative K_i value.

Figure 5: Molecular docking studies of *Vinca* alkaloids. Docking of (A) six *Vinca* alkaloids into a specific common α/β pharmacophore, (B) catharanthine, (C) vindoline, (D) vinblastine, (E) vincristine, (F) vindesine, and (G) vinoelbine.

Figure 6: Induction of mono- and multipolar mitoses and decrease of bipolar mitoses after treatment of SCC114 cells for 24 h with (A) vindoline, (B) catharanthine, or (C) vinblastine as determined by immunofluorescence.

Figure 7: Representative immunofluorescence images of bipolar mitoses of untreated SCC114 cells (upper panel) and of multipolar mitoses of SCC114 cells treated with vinblastine (second panel), catharanthine (third panel), or vindoline (lower panel) for 24 h.

Figure 8: Dendrograms of hierarchical cluster analysis obtained from mRNA expression of genes correlating with $\log_{10}IC_{50}$ values for (A) catharanthine, (B) vindoline, (C) vinblastine, and (D) vincristine. The dendrograms show the clustering of the NCI cell lines.

Figure 9: Assignment of biological functions of gene products associated with cellular response towards catharanthine and vindoline. Genes identified by COMPARE analyses (Table V) were subjected to Ingenuity pathway analysis software. Top 10 biological functions of genes associated with response to (A) catharanthine and (B) vindoline.

Table I: Molecular docking of *Vinca* alkaloids to α/β -tubulin dimer.

Table II: Interaction of *Vinca* alkaloids at the *Vinca* pharmacophore of the α/β -tubulin dimer.

Table III: Resistance profile of multidrug-resistant human CEM/VCR1000 leukemia cells to *Vinca* alkaloids.

Table IV: Correlation of $\log_{10}$ IC₅₀ values for *Vinca* alkaloids of the NCI cell line panel.

* *P*-values, Pearson correlation test.

Table V: Genes identified by standard or reverse COMPARE analyses whose mRNA expression in the NCI cell line panel correlated with IC₅₀ values for *Vinca* alkaloids.

Table VI: Separation of clusters of the NCI cell line panel obtained by hierarchical cluster analysis shown in **Figure 8** in comparison to *Vinca* alkaloids. The $\log_{10}$ IC₅₀ median values (M) of each compound were used as cut-off values to define cell lines as being sensitive or resistant. N.S., not significant ($P>0.05$).

References

- [1] Cragg GM, Grothaus PG, Newman DJ. Impact of natural products on developing new anti-cancer agents. *Chem Rev* 2009;109:3012-43.
- [2] Okouneva T, Hill BT, Wilson L, Jordan MA. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. *Mol Cancer Ther* 2003;2:427-36.
- [3] Gidding CE, Kellie SJ, Kamps WA, de Graaf SS. Vincristine revisited. *Crit Rev Oncol Hematol* 1999;29:267-87.
- [4] Rebacz B, Larsen TO, Clausen MH, Ronnest MH, Loffler H, Ho AD, Kramer A. Identification of griseofulvin as an inhibitor of centrosomal clustering in a phenotype-based screen. *Cancer Res* 2007;67:6342-50.
- [5] Leber B, Maier B, Fuchs F, Chi J, Riffel P, Anderhub S, Wagner L, Ho AD, Salisbury JL, Boutros M, Kramer A. Proteins required for centrosome clustering in cancer cells. *Sci Transl Med* 2010;2:33ra38.
- [6] Zhang L, Yang L, Niu H, Zu Y. Separation of vindoline, catharanthine and vinblastine from *Catharanthus roseus* (L.) G. Don with macroporous adsorption resin. *J Chem Industry Engineering (China)* 2008;59:607-14.
- [7] El-Sayed M, Verpoorte R. *Catharanthus* terpenoid indole alkaloids: Biosynthesis and regulation. *Phytochem Rev* 2007;6:277-305.
- [8] Kimmig A, Gekeler V, Neumann M, Frese G, Handgretinger R, Kardos G, Diddens H, Niethammer D. Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells. *Cancer Res* 1990;50:6793-9.
- [9] Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. *Cancer Res* 1988;48:589-601.
- [10] Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P, Scudiero DA, Monks A, Boyd MR. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. *J Natl Cancer Inst* 1990;82:1113-8.
- [11] Castoldi M, Popova AV. Purification of brain tubulin through two cycles of polymerization-depolymerization in a high-molarity buffer. *Protein Express Purif* 2003;32:83-88.
- [12] Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The protein data bank. *Nucleic Acids Res* 2000;28:235-42.
- [13] Schuttelkopf AW, van Aalten DM. ProDRG: A tool for high-throughput crystallography of protein-ligand complexes. *Acta Crystallogr D Biol Crystallogr* 2004;60:1355-63.
- [14] DeLano WL. The pymol molecular graphics system. DeLano Scientific. San Carlos, CA, USA, 2002.
- [15] Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO, Weinstein JN. A gene expression database for the molecular pharmacology of cancer. *Nat Genet* 2000;24:236-44.
- [16] Amundson SA, Do KT, Vinikoor LC, Lee RA, Koch-Paiz CA, Ahn J, Reimers M, Chen Y, Scudiero DA, Weinstein JN, Trent JM, Bittner ML, Meltzer PS, Fornace AJ, Jr. Integrating global gene expression and radiation survival parameters across the 60 cell lines of the national cancer institute anticancer drug screen. *Cancer Res* 2008;68:415-24.
- [17] Wosikowski K, Schuurhuis D, Johnson K, Paull KD, Myers TG, Weinstein JN, Bates SE. Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. *J Natl Cancer Inst* 1997;89:1505-15.

- [18] Efferth T, Fabry U, Osieka R. Apoptosis and resistance to daunorubicin in human leukemic cells. *Leukemia* 1997;11:1180-6.
- [19] Gigant B, Wang C, Ravelli RB, Roussi F, Steinmetz MO, Curmi PA, Sobel A, Knossow M. Structural basis for the regulation of tubulin by vinblastine. *Nature* 2005;435:519-22.
- [20] Sobolev V, Sorokine A, Prilusky J, Abola EE, Edelman M. Automated analysis of interatomic contacts in proteins. *Bioinformatics* 1999;15:327-32.
- [21] Tang Z, Yang L, Zu Y, Guo X. Variations of vinblastine accumulation and redox state affected by exogenous H_2O_2 in *Catharanthus roseus* (L.) G. Don. *Plant Growth Regul* 2009;57:15-20.
- [22] Quintyne NJ, Reing JE, Hoffelder DR, Gollin SM, Saunders WS. Spindle multipolarity is prevented by centrosomal clustering. *Science* 2005;307:127-9.
- [23] Prakash V, Timasheff SN. Mechanism of interaction of vinca alkaloids with tubulin: Catharanthine and vindoline. *Biochemistry* 1991;30:873-80.
- [24] Cohen-Kashi Malina K, Cooper I, Teichberg VI. Closing the gap between the in-vivo and in-vitro blood-brain barrier tightness. *Brain Res* 2009;1284:12-21.

JOHANNES GUTENBERG
UNIVERSITÄT MAINZ

jgu JOHANNES GUTENBERG-UNIVERSITÄT MAINZ D-55099 Mainz

Professor S.J. Enna
Editor-in-Chief of "Biochemical
Pharmacology"

via: online submission system

Manuscript submission

Dear Prof. Enna,

Enclosed, please, find a manuscript entitled: **"Molecular docking and pharmacogenomics of *Vinca* alkaloids and their monomeric precursors, vindoline and catharanthine."**

Vinblastine and vincristine are dimeric indole alkaloids derived from *Catharanthus roseus*. Their monomeric precursor molecules are vindoline and catharanthine. While there is clear evidence for the action of vinblastine and vincristine as mitotic spindle poisons, not much is known about the monomers vindoline and catharanthine. Both precursor molecules are less cytotoxic than their dimeric drugs, vinblastine and vincristine. In the present investigation, we hypothesized that different cytotoxicities of monomeric precursors and dimeric end products should affect binding to the primary target of *Vinca* alkaloids, the microtubules. A comparative analysis of functional effects of the above mentioned compounds on microtubule formation (effect on $\alpha\beta$ -tubulin polymerisation) has been carried out *in vitro*. The relative binding affinities of vindoline and catharanthine were estimated from Dixon plots assuming that all compounds either directly or indirectly (allosteric modulation) interfere with the [3 H]-vinblastine binding sites in $\alpha\beta$ -tubulin. The experimental data have been compared to molecular modelling *in silico* studies and microarray-based cluster analyses.

The formation of multipolar mitotic spindles by inhibition of centrosomal coalescence has been anticipated as novel treatment strategy. Inhibition of centrosomal clustering represents a novel strategy for cancer drug development and leads to the formation of multipolar spindles with subsequent apoptosis induction. Contribution to cell death by interference with spindle polarity has been shown for vinblastine by us for the first time.

In light of these results, we would be pleased, if you find this manuscript worth publishing in "Biochemical Pharmacology".

Sincerely yours

(Prof. Dr. Thomas Efferth)

Fachbereich Chemie, Pharmazie
und Geowissenschaften

Institut für Pharmazie und
Biochemie

Prof. Dr. Thomas Efferth
Abteilungsleiter

Johannes Gutenberg-
Universität Mainz

Staudinger Weg 5
D-55099 Mainz

Tel. +49(0)6131-39 25751
Fax +49(0)6131-39 23752

efferth@uni-mainz.de

[www.pharmazie.uni-
mainz.de/akefferth.htm](http://www.pharmazie.uni-mainz.de/akefferth.htm)

Info-Bereich 1

Datum 17.11.2010

Ihre Zeichen/Nachricht

Unsere Zeichen/Nachricht

Sekretariat

Info-Bereich 2

Verteiler

Anlage

Zweit-Adresse

Vertretungen

Table I: Molecular docking of *Vinca* alkaloids to α/β -tubulin dimer.

Compound	Mean Docking energy (kcal/mol)	Mean pKi value (μM)
Vindesine	-8.52	1.49
Vincristine	-8.50	2.05
Vinorelbine	-8.47	1.54
Vinblastine	-8.37	1.67
Vindoline	-7.28	4.72
Catharanthine	-7.00	7.34

* pKi, predicted inhibitory constant

Table II: Interaction of *Vinca* alkaloids at the *Vinca* pharmacophore of the α/β -tubulin dimer.

	Residues involved in H-Bond interaction with ligand	No of residues involved in hydrophobic interactions with the ligand
Vinblastine	ASN249C; LYS176B; PRO175B; SER178B; TYR210B; VAL177B; VAL353C	13
Vincristine	ASN249C; ASN329C; LYS336C; PRO222B; TYR210B; VAL177B	15
Vindesine	ASN249C; ASN329C; PRO175B; VAL177B; VAL353C	12
Vinorelbine	ASN329C; PRO175B; PRO222B; VAL353C	13
Vindoline	ASN249C; ASN329C; PRO222B; VAL177B	9
Catharanthine	none	9

Table III: Resistance profile of multidrug-resistant human CEM/VCR1000 leukemia cells to *Vinca* alkaloids.

	CCRF-CEM (Mean IC ₅₀ ± SD, μM)	CEM/VCR1000 (Mean IC ₅₀ ± SD, μM)	Degree of Resistance
Catharanthine	13.7 ± 4.5	29.8 ± 1.22	2.2
Vindoline	14.0 ± 6.28	24.1 ± 3.67	1.7
Vincristine	1.92 ± 0.14	80.2 ± 10.2	41.8
Vinblastine	0.468 ± 0.06	26.3 ± 1.6	56.2
Vindesine	2.93 ± 0.02	229 ± 24.4	78.2
Vinorelbine	0.031 ± 0.006	10.6 ± 0.89	341.9

Table IV: Correlation of log₁₀ IC₅₀ values for *Vinca* alkaloids of the NCI cell line panel.* *P*-values, Pearson correlation test

		Vindoline	Vinblastine	Vincristine
Catharanthine	R-Value	0.311	0.015	-0.015
	P-Value	0.010	0.455	0.455
Vindoline	R-Value		-0.088	0.078
	P-Value		0.261	0.283
Vinblastine	R-Value			0.789
	P-Value			6.518×10 ⁻¹⁶

Table V: Genes identified by standard or reverse COMPARE analyses whose mRNA expression in the NCI cell line panel correlated with IC₅₀ values for *Vinca* alkaloids.

COMPARE Coefficient	Gene Symbol	GeneBank Acc. No.	Pattern ID	Gene Name	Gene Function
Catharanthine: Standard COMPARE					
0.591	<i>FLNB</i>	AF042166	GC55768	filamin B, beta (actin binding protein 278)	filamin family member; links transmembrane proteins with actin cytoskeleton; repair of vascular injuries
0.554	<i>NFE2L3</i>	NM_004289	GC183078	Rho-guanine nucleotide exchange factor	leucine zipper transcription factor family member; involved in antioxidant response
0.55	null	AA455079	GC148639	unknown	unknown
0.548	<i>PODXL</i>	AI940225	GC79478	unknown	unknown
0.546	<i>PODXL</i>	U97519	GC30864	podocalyxin-like	anti-adhesin
0.545	null	AA010617	GC39732	unknown	unknown
0.543	null	NM_022448	GC189007	unknown	unknown
Catharanthine: Reverse COMPARE					
-0.625	<i>DLGAP2</i>	AI221403	GC61102	discs, large (Drosophila) homolog-associated protein 2	membrane-associated guanylate kinase; neuronal cell signaling
-0.589	null	R28285	GC93180	unknown	unknown
-0.575	null	R07477	GC92891	unknown	unknown
-0.527	null	AA747713	GC49278	unknown	unknown
-0.526	null	AI972104	GC80541	unknown	unknown
-0.518	null	AI382058	GC64460	unknown	unknown
-0.505	null	T95652	GC95840	unknown	unknown
-0.504	<i>TFIP11</i>	AL080147	GC164410	11 tuftelin interacting protein	spliceosome disassembly; pre-mRNA splicing
-0.503	<i>IKZF4</i>	AI261467	GC61722	4 IKAROS family zinc finger	Ikaros transcription factor family member
-0.502	<i>KCTD15</i>	AA018217	GC39879	15 potassium channel tetramerization domain containing	unknown
Vindoline: Standard COMPARE					
0.745	null	NM_016164	GC186831		unknown
0.718	null	AI688023	GC70500		unknown
0.715	<i>ZNF414</i>	AW291109	GC169427	zinc finger protein 414	transcriptional regulation
0.674	<i>FBXO21</i>	U79257	GC191569	F-box protein 21	phosphorylation-dependent ubiquitination
0.657	<i>RAB3B</i>	M28214	GC32518	RAS family member 3B	vesicular protein transport (by similarity)
0.652	<i>HAS1</i>	NM_001523	GC181059	hyaluronan synthase 1	constituent of the extracellular matrix; wound healing and tissue repair; tumor metastasis
0.651	<i>KIAA1267</i>	AL042870	GC82405	KIAA1267	unknown
0.643	<i>C19orf47</i>	BE297801	GC172893	chromosome 19 open reading frame 47	unknown
0.644	null	M73255	GC90241	unknown	unknown
0.637	null	M15205	GC32801	unknown	unknown
Vindoline: Reverse COMPARE					
-0.651	null	AA894854	GC51907	unknown	unknown
-0.636	<i>ZCWPW2</i>	AI677721	GC69927	zinc finger, CW type with PWWP domain 2	zinc-binding protein
-0.633	<i>PSKH1</i>	W25248	GC98337	protein serine kinase H1	splicing factor compartment-associated serine kinase intracellular SR-protein traffic, pre-mRNA processing
-0.631	null	AI677570	GC69940	unknown	unknown
-0.621	null	AI668886	GC69495	unknown	unknown
-0.612	<i>RHAG</i>	AI052264	GC57850	Rh-associated glycoprotein	transports ammonium and carbon dioxide across

-0.608	null	AI823587	GC76424	unknown	the blood cell membrane
-0.607	null	AA805746	GC50354	unknown	unknown
-0.602	null	R62547	GC93996	unknown	unknown
-0.598	null	AA876132	GC51488	unknown	unknown
Vinblastine: Standard COMPARE					
0.531	N21238	GC90658	null	unknown	unknown
0.514	MAP6	AI885733	GC77780	microtubule-associated protein 6	microtubule-associated protein; calmodulin-regulated
0.507	H79317	GC87964	null	unknown	protein involved in microtubule stabilization
Vinblastine: Reverse COMPARE					
-0.777	ABCC6	U66689	GC29666	ATP-binding cassette, sub-family C (CFTR/MRP), member 6	ATP-binding cassette (ABC) transporter; transports glutathione conjugates as leukotriene-c4 (LTC4) and N-ethylmaleimide S-glutathione (NEM-GS)
-0.684	null	AF338650	GC154580	unknown	unknown
-0.671	CLDN1	AI889132	GC77925	claudin 1	claudin family member; integral membrane protein and component of tight junctions
-0.668	KLF8	AI821447	GC160084	Kruppel-like factor 8	Sp/KLF transcription factor family member; regulation of epithelial to mesenchymal transition
-0.662	null	AI884781	GC160541	unknown	unknown
-0.632	null	R26843	GC93170	unknown	unknown
Vincristine: Standard COMPARE					
0.557	ENTPD1	AA493246	GC45226	ectonucleoside triphosphate diphosphohydrolase 1	hydrolysis of ATP in the nervous system and prevention of platelet aggregation
0.52	null	AA229646	GC42534	unknown	unknown
0.518	LOC648987	AI056871	GC57995	hypothetical LOC648987	unknown
Vincristine: Reverse COMPARE					
-0.762	GNMT	AF101477	GC152741	glycine N-methyltransferase	regulation of metabolism of methionine
-0.676	PRLR	AF349939	GC154656	prolactin receptor	prolactin receptor
-0.674	null	AI820661	GC160054	unknown	unknown
-0.674	BNIP1	W69365	GC99195	CL2/adenovirus E1B 19kD	involved in apoptosis
-0.673	null	AW300488	GC169739	interacting protein like	unknown
-0.671	TGFB3	J03241	GC178532	transforming growth factor, β 3	member of the TGF-beta family; involved in embryogenesis and cell differentiation
-0.65	null	AC004142	GC38728	unknown	unknown
-0.663	CLDN1	NM_021101	GC188640	claudin 1	claudin family member; integral membrane protein and component of tight junctions
-0.653	KIAA1161	AB032987	GC151276	KIAA1161	putative glucosidase (by similarity)

Information on gene functions was taken from the OMIM database, NCI, USA (<http://www.ncbi.nlm.nih.gov/Omim/>) and from the GeneCard database of the Weizman Institute of Science, Rehovot, Israel (<http://bioinfo.weizmann.ac.il/cards/index.html>).

Table VI: Separation of clusters of the NCI cell line panel obtained by hierarchical cluster analysis shown in **Figure 8** in comparison to *Vinca* alkaloids. The $\log_{10}$ IC₅₀ median values (M) of each compound were used as cut-off values to define cell lines as being sensitive or resistant. N.S., not significant ($P>0.05$).

		Partition	Cluster 1	Cluster 2	Cluster 3	χ^2 Test
Catharanthine (n=48)	sensitive	<-4.358	5	9	10	P=0.01147
	resistant	>-4.358	0	5	19	
Vindoline (n=48)	sensitive	<-3.786	9	1	14	P=1.69×10 ⁻⁴
	resistant	>-3.786	0	11	13	
Vinblastine (n=58)	sensitive	<-9.130	3	9	6	N.S.
	resistant	>-9.130	10	13	17	
Vincristine (n=58)	sensitive	<-6.8955	10	7	12	N.S.
	resistant	>-6.8955	5	3	21

Figure 2
[Click here to download high resolution image](#)

Figure 3
[Click here to download high resolution image](#)

Figure 4
[Click here to download high resolution image](#)

Figure 6
[Click here to download high resolution image](#)

Figure 8
[Click here to download high resolution image](#)

A. Catharanthine

B. Vindoline

C. Vinblastine

D. Vincristine

Graphical Abstract

Vinblastine produced high fractions of mono- and multipolar mitotic spindles, while its monomeric precursor molecules, vindoline and catharanthine did only weakly affect bipolar mitotic spindle formation. Inhibition of centrosomal clustering represents a novel strategy for cancer drug development and leads to the formation of multipolar spindles with subsequent apoptosis induction.